Roche Glycart AG
https://www.roche.ch/en/sites/schlieren
8952 Schlieren, Wagistrasse 10
+41 43 215 10 00
The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.
Roche Glycart AG
Wagistrasse 10
8952 Schlieren
98 Ergebnisse für "immunotherapy" unter Roche Glycart AG
Roche - Immunotherapy at Roche
... Neuroscience Our approach to cancer immunotherapy Some people can point to a book that changed ... Immunotherapy Development at Roche. For decades, researchers trying to devise new treatments for cancer have ... Roche - Immunotherapy at Roche ... https://www.roche.com/research_and_development/what_we_are_working_on/oncology/cancer- immunotherapy ... Roche - Immunotherapy at Roche ...
Somagenetix
https://www.wysszurich.ch/projects/somagenetix
8952 Schlieren, Wagistrasse 23
Gene therapy solutions for patients with severe inherited diseases.
Somagenetix
Wagistrasse 23
8952 Schlieren
253 Ergebnisse für "immunotherapy" unter Somagenetix
UZH - UZH News - Anaveon Immunotherapy
... Life Sciences Spin-off Anaveon Backs Immunotherapy Onur Boyman, an immunologist working at the ... BaseLaunch healthcare accelerator program. Boosting interleukin-2 Immunotherapy is an umbrella term for a ... UZH - UZH News - Anaveon Immunotherapy ... UZH - UZH News - Anaveon Immunotherapy Home Main navigation Search Jump to content Breadcrumb All ... UZH - UZH News - Anaveon Immunotherapy ...
Immunotherapy of Alzheimer disease - Zurich Open Repository and Archive
... Nitsch, R M (2004). Immunotherapy of Alzheimer disease. Alzheimer Disease and Associated Disorders ... Immunotherapy of Alzheimer disease - Zurich Open Repository and Archive ... Immunotherapy of Alzheimer disease - Zurich Open Repository and Archive Header Quicknavigation Home ... Immunotherapy of Alzheimer disease - Zurich Open Repository and Archive ...
ImmunOs Therapeutics AG
http://immunostherapeutics.com/
8952 Schlieren, Wagistrasse 14
ImmunOs Therapeutics AG is a clinical-stage biotechnology company developing the next generation of novel immunotherapies that enhance the efficacy of market leading checkpoint inhibitors and costimulatory agonists for cancer therapy. The company is actively discussing and exploring new strategic collaborations with leading global pharmaceutical companies.
ImmunOs Therapeutics AG
Wagistrasse 14
8952 Schlieren
21 Ergebnisse für "immunotherapy" unter ImmunOs Therapeutics AG
Background on Cancer Immunotherapy - Immunostherapy
... Contact Background on Cancer Immunotherapy Current approaches in cancer immunotherapy focus mainly ... prevent T cells from eliminating cancer cells (checkpoint inhibitors). Cancer immunotherapy has been a ... Background on Cancer Immunotherapy - Immunostherapy ... https://www.immunostherapeutics.com/approach/background-on-cancer- immunotherapy/ ... Background on Cancer Immunotherapy - Immunostherapy ...
Investors | Immunos Therapeutics
... private investors. The Company has built a preclinical portfolio of novel immunotherapy candidates and is ... Company has built a preclinical portfolio of novel immunotherapy candidates and is currently exploring ...
Neurimmune Therapeutics AG
8952 Schlieren, Wagistrasse 18
+41 44 755 46 46
info@neurimmune.com
Neurimmune is a biopharmaceutical company dedicated to the development of immunotherapeutics for the treatment and prevention of human disorders with a focus on protein aggregation diseases.
Neurimmune Therapeutics AG
Wagistrasse 18
8952 Schlieren
10 Ergebnisse für "immunotherapy" unter Neurimmune Therapeutics AG
Neurimmune - Lab Insights: Immunotherapy for Type-2 diabetes
... All News and Press Releases Lab Insights: Immunotherapy for Type-2 diabetes Neurimmune is pursuing ... the development of an innovative antibody-based program for the immunotherapy of type-2 diabetes, and ... Neurimmune - Lab Insights: Immunotherapy for Type-2 diabetes ... http://www.neurimmune.com/stories/lab-insights- immunotherapy-for-type-2-diabetes.html ... Neurimmune - Lab Insights: Immunotherapy for Type-2 diabetes ...
Neurimmune - About Neurimmune
... exclusive rights to three immunotherapy programs with human monoclonal antibodies targeting alpha-synuclein ... executing an agreement granting worldwide exclusive rights to three immunotherapy programs with human ...
ETH Zürich - Numerische Materialmodellierung
8005 Zürich, Technoparkstrasse 1 / Einstein PFA G 11 (2. OG)
ETH Zürich - Numerische Materialmodellierung
Technoparkstrasse 1
8005 Zürich
53 Ergebnisse für "immunotherapy" unter ETH Zürich - Numerische Materialmodellierung
Call for a holistic framework for cancer immunotherapy - Research C...
... it. Cancer immunotherapy outcomes are shaped by various soft variables including diet/microbiome ... immunotherapy to enhance treatment response and improve quality of life. Publication status Notes Commentary ... Call for a holistic framework for cancer immunotherapy - Research Collection ... Call for a holistic framework for cancer immunotherapy - Research Collection Header Upper Right ... Call for a holistic framework for cancer immunotherapy - Research Collection ...
The tumor organismal environment: Role in tumor development and can...
... The tumor organismal environment: Role in tumor development and cancer immunotherapy ETH ... Bibliography Abstract Tumor immunotherapy has resulted in dramatic effects in some cancer types, including ... The tumor organismal environment: Role in tumor development and cancer immunotherapy - Research ... The tumor organismal environment: Role in tumor development and cancer immunotherapy - Research ... The tumor organismal environment: Role in tumor development and cancer immunotherapy - Research ...
ETH Zürich - Feasibility Lab
Technoparkstrasse 1
8005 Zürich
90 Ergebnisse für "immunotherapy" unter ETH Zürich - Feasibility Lab
Major step towards individual cancer immunotherapy | ETH Zurich
... Major step towards individual cancer immunotherapy | ETH Zurich ... Major step towards individual cancer immunotherapy | ETH Zurich Homepage Navigation Search Content ... Major step towards individual cancer immunotherapy | ETH Zurich ...
Engineering T-cell receptors for cancer immunotherapy – Department ...
... applying the platform for engineering T cell receptors for cancer immunotherapy. 28.09.2022 Find the ... Engineering T-cell receptors for cancer immunotherapy – Department of Biosystems Science and ... Engineering T-cell receptors for cancer immunotherapy – Department of Biosystems Science and ... Engineering T-cell receptors for cancer immunotherapy – Department of Biosystems Science and ...
University Hospital Zurich, Research and Education Office
https://www.usz.ch/forschung/Seiten/default.aspx
8091 Zürich, Rämistrasse 100
The University Hospital Zurich is one of Switzerland’s largest hospitals and a pioneering institution in the field of clinical research. In its 40 departments and institutes, it assembles and practices all medical disciplines and enjoys an excellent reputation for state-of-the-art medicine, professional and com- passionate patient care, and groundbreaking bench-to-bedside translational medical research.
University Hospital Zurich, Research and Education Office
Rämistrasse 100
8091 Zürich
134 Ergebnisse für "immunotherapy" unter University Hospital Zurich, Research and Education Office
Research activities in Immunotherapy of the Department of Dermatolo...
... Kündig & Pål Johansen Main fields of research Our research focused on immunotherapy of allergies ... clinical studies in humans. In allergy, we aim to improve efficacy and safety of allergen immunotherapy ... Research activities in Immunotherapy of the Department of Dermatology – Universitätsspital Zürich ... https://new.usz.ch/fachbereich/dermatologie/forschung/ immunotherapy/ ... Research activities in Immunotherapy of the Department of Dermatology – Universitätsspital Zürich ...
5th Zurich Immuno-Oncology Symposium – Universitätsspital Zürich
... The number of malignancies where immunotherapy has gained approval has rapidly grown, and ... increasingly, immunotherapy is being combined with other treatment modalities. This advancement of science and ... Symposium The number of malignancies where immunotherapy has gained approval has rapidly grown, and ... increasingly, immunotherapy is being combined with other treatment modalities. This advancement of science and ...
University of Zurich
https://www.campus-schlieren.uzh.ch/en.html
8952 Schlieren, Wagistrasse 12
The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.
University of Zurich
Wagistrasse 12
8952 Schlieren
143 Ergebnisse für "immunotherapy" unter University of Zurich
The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive ...
... Tumor Immunotherapy Zingg, Daniel ; Arenas-Ramirez, Natalia ; Sahin, Dilara ; Rosalia, Rodney A ... Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy. Cell Reports, 20(4):854-867 ... Immunotherapy ... Immunotherapy - Zurich Open Repository and Archive Header Quicknavigation Home Navigation Content Contact Search ... Immunotherapy ...
Immune regulation by intralymphatic immunotherapy with modular alle...
... Immune regulation by intralymphatic immunotherapy with modular allergen translocation MAT vaccine ... BACKGROUND: Allergen-specific immunotherapy (SIT) faces problems related to side effects and limited efficacy ... Immune regulation by intralymphatic immunotherapy with modular allergen translocation MAT vaccine - ... Immune regulation by intralymphatic immunotherapy with modular allergen translocation MAT vaccine ... Immune regulation by intralymphatic immunotherapy with modular allergen translocation MAT vaccine - ...
Bio-Technopark Schlieren-Zürich
8952 Schlieren, Wagistrasse 23
+41 76 336 99 44
mario.jenni@bio-technopark.ch
The Bio-Technopark offers professional support for life science start-ups in the setting up and expansion of business activities and promotes interaction between start-ups, academia and industry. A nationally and internationally respected science park has grown up at Schlieren. Through stringent selection, coaching and support, more than 30 successful start-up companies with 750 employees are located here. Eight have been acquired by large corporates, but are still active in the park. Together with 20 institutes and clinics from the University and University Hospital Zurich, an innovative mix of very young and well-established companies and academic research groups has emerged.
Bio-Technopark Schlieren-Zürich
Wagistrasse 23
8952 Schlieren
14 Ergebnisse für "immunotherapy" unter Bio-Technopark Schlieren-Zürich
MEMO THERAPEUTICS AG IDENTIFIES POTENT SARS-COV-2-NEUTRALIZING ANTI...
... COVID-19 immunotherapy. MTx’s DROPZYLLA® platform isolated ultra-rare and highly potent virus ... as a COVID-19 immunotherapy Since March, MTx has selected the most promising donors from hundreds of ... -neutralizing antibodies with the potential for development as a COVID-19 immunotherapy. MTx’s DROPZYLLA ... six weeks SARS-CoV-2-specific antibodies to be developed as a COVID-19 immunotherapy Since March, MTx ...
Virometix Closes Financing Round › BIO-TECHNOPARK® Schlieren-Zürich
... immunotherapy. The investment was backed by existing shareholders and new private investors with longstanding ... support further development of its vaccine candidates for RSV and cancer immunotherapy. The investment was ...
Virometix AG
8952 Schlieren, Wagistrasse 14
+41 (0)43 433 86 60
info@virometix.com
Virometix AG is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases.
Virometix AG
Wagistrasse 14
8952 Schlieren
5 Ergebnisse für "immunotherapy" unter Virometix AG
Microsoft Word - 200709 Joint PR Anergis_Virometix_HZI_final_approv...
... Allergy Immunotherapy - Study is performed at the Helmholtz Centre for Infection Research and supported by ... Contiguous Overlapping Peptides (COPs) for ultra-fast allergy immunotherapy, and Virometix AG, a company ... Allergy Immunotherapy - Study is performed at the Helmholtz Centre for Infection Research and supported by ... Contiguous Overlapping Peptides (COPs) for ultra-fast allergy immunotherapy, and Virometix AG, a company ...
Newsroom - Virometix AG
... Virus-Like Particles for Ultra-Fast Allergy Immunotherapy Study is performed at the Helmholtz Centre for ... company developing Contiguous Overlapping Peptides (COPs) for ultra-fast allergy immunotherapy, and ... Immunotherapy Study is performed at the Helmholtz Centre for Infection Research and supported by a TRANSVAC2 ... Peptides (COPs) for ultra-fast allergy immunotherapy, and Virometix AG, a company developing a new ...